Safety of factor VIII inhibitor bypass activity (FEIBA®): 10-year compilation of thrombotic adverse events

Haemophilia

Volumn 8, Issue 2, 2002, Pages 83-90

  Ehrlich, Hartmut J ^a   Henzl, M J ^a   Gomperts, E D ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Adverse drug reaction reporting systems; Blood coagulation factor inhibitors; Factor VIII; Product surveillance; Safety; Thrombosis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; LIPID;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ANTAGONISM; DRUG SURVEILLANCE PROGRAM; FEMALE; HEART INFARCTION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INCIDENCE; INTOXICATION; MALE; MIDDLE AGED; PRESCHOOL CHILD; RISK FACTOR; THROMBOSIS; ADOLESCENT; CANCER MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG OVERDOSE; DRUG SAFETY; FREQUENCY ANALYSIS; HEMOPHILIA; LIPID BLOOD LEVEL; LUNG EMBOLISM; MEDICAL DOCUMENTATION; OBESITY; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OVERDOSE; RISK FACTORS; THROMBOSIS;

EID: 0036489638     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00532.x     Document Type: Article

References (36)

1. Ehrlich HJ, Bray GL, Gomperts ED. Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A. Thromb Haemost 1998; 79: 242-3.
2. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Kaiml M, Kornhuber B. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates. Vox Sang 1999; 77: 3-8.
3. Penner JA. Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate AUTOPLEX T. Haemophilia 1999; 5 (Suppl. 3): 1-9.
4. Hilgartner MW, Knatterud GL, FEIBA Study Group. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
5. Hilgartner M, Aledort L, Andes A, Gill J, FEIBA Study Group. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990; 30: 626-30.
6. Aledort L. Inhibitors in hemophilia patients: current status and management. Am J Hematol 1994; 47: 208-17.
7. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P, French FEIBA Study Group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
8. Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999; 5 (Suppl. 3): 11-7.
9. Zupancic-Salek S, Radman I, Labar B. Perioperative treatment with recombinant factor VIIa in haemophilic patient with massive intraabdominal bleeding. Thromb Haemost 1997; 77 (Suppl.): PS-203.
10. DellaCroce FJ, Kountakis S, Aguilar EF. Manifestations of factor VIII inhibitor in the head and neck. Arch Otolaryngol Head Neck Surg 1999; 125: 1258-61.
11. Baxter BioScience Pharmacovigilance Database (data on file).
12. Mizon P, Goudemand J, Jude B, Marey A. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. Ann Hematol 1992; 64: 309-11.
13. Karayalcin G, Goldberg B, Cherrick I, Kurer C, Bierman F, Lanzkowsky P. Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8-year-old boy with hemophilia A and factor VIII inhibitor. Am J Pediatr Hematol Oncol 1993; 15: 416-9.
14. Rocino A. Il ruolo dei concentrati di complesso protrombinico attivato. In: Triennial Convention on the Clinical and Social Problems of Hemophilia, Sorrento, Italy, 1996. Montreal: WFH, 1996.
15. Gruen DR, Winchester PH, Brill PW, Ramirez E. Magnetic resonance imaging of myocardial infarction during prothrombin complex concentrate therapy of hemophilia A. Pediatr Radiol 1997; 27: 271-2.
16. Wenke A, Aygören-Pürsün E, Ehrenforth S, Krause M, Ludwig G, Scharrer I. Verlauf bei 13 Patienten Mit Erworbener Hemmkörperhämophilie. In: Scharrer I, Schramm W, eds. Hämophilie-Symposion Hamburg 1998. Hamburg, Germany: Springer, 1998: 247-55.
17. Christiansen SE, Ingerslev J, Wallevik K, Farso F, Helmig O, Stenbjerg S. Management of anterior compartment syndrome in two high responder factor VIII inhibitor patients with activated prothrombin complex concentrate. Thromb Res 1986; 42: 707-12.
18. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ 1998; 316: 1295-8.
19. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol 1998; 45: 427-31.
20. Bennett CL, Connors JM, Carwile JM et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-7.
21. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 717-21.
22. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Arias LH. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 1998; 54: 483-8.
23. Kimmel SE, Sekeres MA, Berlin JA, Goldberg LR, Strom BL. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. J Clin Epidemiol 1998; 51: 1-10.
24. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001; 358: 1872-3.
25. Aledort LM. Recombinant factor VIIa is a pan-hemostatic agent? Thromb Haemost 2000; 83: 637-8.
26. Stein SF, Duncan A, Cutler D, Glazer S. Disseminated intravascular coagulation (DIC) in a hemophiliac treated with recombinant factor VIIa. Blood 1990; 76 (Suppl. 1): 438.
27. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993; 7: 78-83.
28. Macik BG. Treatment of factor VIII inhibitors: products and strategies. Semin Thromb Hemost 1993; 19: 13-24.
29. Schmidt ML, Gamerman S, Smith HE, Scott JP, DiMichele DM. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am J Hematol 1994; 47: 36-40.
30. Hay CRM, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa. Haemophilia 1996; 2 (Suppl. 1): 157.
31. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78: 1463-7.
32. Stielties N, Ounnoughhene N, Vassilieff D, Sultan Y. Failure of recombinant factor VIIa to control surgical bleeding in a severe hemophilia A patient with an inhibitor and possible DIC. Thromb Haemost 1997; 77 (Suppl.): PS-202.
33. Juvonen E, Kolho E, Anttila VJ, Lommi J, Nissinen M, Rasi V. Acute myocardial infarction complicating therapy with FVIII followed by APCC and rFVIIa in a 26-year-old man with haemophilia A and FVIII inhibitor. Haemophilia 1998; 4: 338.
34. Schulman S. rFVIIa-CI Group. Safety, efficacy and lessons from continuous infusion with rFVIIa. Haemophilia 1998; 4: 564-7.
35. Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-6.
36. Liebman HA, Chediak J, Fink KI, Galvez AG, Shah PC Sham RL. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 2000; 63: 109-13.